Osteopore Limited (ASX: OSX) has announced a partnership with the Tam Shiu Anatomical Modelling Laboratory at the University of Hong Kong, alongside plans to establish its second Global Centre of Excellence. This marks the Osteopore Hong Kong Centre of Excellence as the company’s first GCoE outside Singapore, following the Hong Kong distribution agreement announced on 22 January 2026.
The partnership centres on enhancing digital design capabilities for orthopaedic interventions, whilst the GCoE will support the commercial launch of customised orthopaedic implants in Hong Kong. The Tam Shiu AML, established in 2018, currently serves more than 300 patients each year with complex pathologies requiring specialised 3D digital technology for intervention planning.
This strategic expansion follows Osteopore’s established framework in Singapore, where the company set up its first GCoE with SingHealth in May 2024. The Hong Kong initiative positions the company to execute on its Asia-Pacific expansion strategy with institutional backing from a leading regional university, whilst potentially accessing the broader Greater Bay Area market.
Partnership focuses on digital design and surgical workflow capabilities
The collaboration between Osteopore and Tam Shiu AML encompasses several technical areas:
- Cross-pollination of experiences in digital modelling and design of cutting jigs and fixtures
- Development of intraoperative use models and surgical guides
- Knowledge sharing on digital reconstruction of bone gaps and augmentation sites throughout the body
- Specific focus on converting designs into implantable custom devices for the Hong Kong market
The partnership aims to strengthen Osteopore’s core competencies in design and manufacturing, enhancing the company’s engagement opportunities with surgeons and the broader hospital ecosystem. This technical collaboration is reported to support Osteopore’s design capabilities ahead of the planned commercial orthopaedic implant launch in Hong Kong, enabling more precise customisation for complex bone reconstruction cases.
What is a Centre of Excellence in medical devices?
A Global Centre of Excellence (GCoE) functions as a collaborative framework where medical device companies work alongside clinical institutions to co-develop, test, validate and scale products before full market launch. The model embeds manufacturers within clinical ecosystems, allowing for real-world testing and refinement of devices alongside practising surgeons.
Osteopore’s first GCoE, established with SingHealth in May 2024, provided this operational template. The framework enables collaboration with clinicians whilst accelerating product adoption by integrating feedback from actual surgical cases into device development. For medical device companies, GCoEs reduce commercialisation risk by validating products within clinical settings prior to broader market deployment, addressing potential design or workflow issues before they impact commercial rollout.
CEO Commentary
“The GCoE initiative established in Singapore in 2024 has empowered us in the area of customised implant design for complex bone reconstruction, and we look forward to bringing that expertise to Hong Kong and potentially, the Greater Bay Area.” — Dr Yujing Lim, CEO
Hong Kong as gateway to the Greater Bay Area
The strategic selection of Hong Kong relates to regulatory harmonisation initiatives facilitating cross-border use of medical devices across the Greater Bay Area. These initiatives support collaborative innovation across the region’s healthcare infrastructure, potentially enabling devices registered in Hong Kong to be used in designated healthcare institutions throughout the broader area.
The Greater Bay Area encompasses extensive healthcare infrastructure across multiple cities, representing substantially larger patient populations than Hong Kong alone. CEO Dr Yujing Lim identified the Greater Bay Area as “a region of significant commercial interest” for Osteopore, suggesting the Hong Kong GCoE could function as an entry point to Chinese healthcare markets through established regulatory pathways.
This positioning could provide Osteopore with access to a market where local clinical and research facilities are already integrating 3D digital modelling to support complex orthopaedic interventions and personalised instrument production, indicating existing adoption of 3D printing technologies in surgical practice.
Market opportunity in 3D-printed orthopaedic implants
The global 3D-printed orthopaedic implants market is forecast to reach USD 7.5 billion by 2035, growing at a compound annual growth rate (CAGR) of 14.5% from 2026 to 2035. Growth drivers include customisation capabilities, improved fit compared to standardised implants, and faster production times versus traditional manufacturing methods.
| Metric | Value |
|---|---|
| Global market forecast (2035) | USD 7.5 billion |
| Growth rate (CAGR) | 14.5% |
| Tam Shiu AML patients served annually | 300+ |
| Osteopore GCoEs globally | 2 |
Hong Kong’s orthopaedic bone filler and bone implant segment is reported to be increasingly integrating advanced 3D printing technologies, positioning the region to capitalise on innovation in patient-specific implants, surgical guides and pre-operative models that enhance precision and clinical outcomes. Osteopore’s positioning within this high-growth segment, supported by institutional partnerships, provides infrastructure for commercialisation as adoption of customised orthopaedic devices accelerates.
Partner credentials strengthen clinical pathway
The Tam Shiu AML is led by Clinical Associate Professor Christian Fang Xinshuo, who serves as Deputy Chief of the Division of Orthopaedic Trauma at the University of Hong Kong. Professor Fang’s credentials and clinical network include:
- Honorary consultant at HKU with clinical service across Queen Mary Hospital, Gleneagles Hong Kong Hospital, and Hong Kong University Shenzhen Hospital
- Clinical focus on orthopaedic trauma surgery, osteoporosis, polytrauma, pelvic acetabular fractures and clinical applications of 3D printing
- Recipient of the Harry Fang gold medal award from the Hong Kong College of Orthopaedic Surgeons
- Active faculty member for the AO Foundation, SICOT, and Hong Kong College of Orthopaedic Surgeons
- Faculty and organiser of over 40 international courses and educational events
- Overseas training in Germany, Switzerland, China, Singapore, the United Kingdom and Australia
Professor Fang is reported to be heavily engaged in clinical training of younger orthopaedic surgeons, providing Osteopore with access to a surgeon training network across multiple Hong Kong hospitals. This partnership with an influential clinical leader could support both surgeon adoption and integration of Osteopore’s technology into training curricula for emerging orthopaedic specialists.
Next steps for Osteopore in Hong Kong
The Osteopore Hong Kong Centre of Excellence announcement represents the latest step in the company’s methodical Hong Kong market entry strategy. Following the 22 January 2026 distribution agreement for orthopaedic products in Hong Kong, the company has now aligned distribution channels, design partnerships and clinical infrastructure to support commercial launch.
The APAC GCoE is positioned to support Osteopore’s commercial launch of customised orthopaedic implants in Hong Kong by providing the clinical validation framework established in Singapore. Sequential announcements over recent weeks demonstrate execution on stated expansion objectives, with distribution agreements, university partnerships and GCoE infrastructure now in place ahead of product commercialisation.
CEO Commentary
“We’re glad to form a partnership with Professor Fang and his team at the University of Hong Kong, to develop core competencies that will eventually support our commercial intent.” — Dr Yujing Lim, CEO
The establishment of the second GCoE outside Singapore signals Osteopore’s broader Asia-Pacific expansion strategy, with Hong Kong functioning as a strategic entry point to the Greater Bay Area market. The company’s methodical approach, building institutional partnerships and clinical infrastructure prior to full commercial launch, aims to de-risk market entry whilst establishing credibility within Hong Kong’s orthopaedic community.
Want more Biotech breakthroughs delivered to your inbox?
Osteopore’s strategic expansion into Hong Kong demonstrates the rapid pace of innovation across ASX-listed Biotech and Healthcare companies. For investors tracking the sector’s evolution, timely access to breaking news and comprehensive analysis is essential. StockWire X delivers FREE Big News Blasts covering Non-Resource ASX sectors including Biotech, Healthcare, Technology, Finance and Industrials—trusted by over 20,000 active subscribers who receive breaking announcements alongside detailed context explaining what developments mean for company fundamentals and market positioning.
Readers interested in Biotech sector updates can access these alerts by clicking the “Free Alerts” button in the site header to subscribe to Big News Blasts, ensuring no significant ASX announcements across Non-Resource sectors are missed whilst gaining professional-grade analysis without subscription fees.
